CAS NO: | 2374740-21-1 |
包装 | 价格(元) |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
Cas No. | 2374740-21-1 |
Canonical SMILES | CNC(C[C@H]1NC[C@@H](NC(C2=CC(C3=C(Cl)C=NN3C)=C(Cl)O2)=O)[C@H](C4=CC(F)=C(F)C=C4)C1)=O |
分子式 | C23H23Cl2F2N5O3 |
分子量 | 526.36 |
溶解度 | Soluble in DMSO |
储存条件 | Store at -20°C |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
半岛bd体育手机客户端 描述 | AKT-IN-3 (compound E22) is a potent, orally active low hERG blocking Akt inhibitor, with 1.4 nM, 1.2 nM and 1.7 nM for Akt1, Akt2 and Akt3, respectively. AKT-IN-3 (compound E22) also exhibits good inhibitory activity against other AGC family kinases, such as PKA, PKC, ROCK1, RSK1, P70S6K, and SGK. AKT-IN-3 (compound E22) induces apoptosis and inhibits metastasis of cancer cells[1]. Akt1|1.4 nM (IC50)|Akt2|1.2 nM (IC50)|Akt3|1.7 nM (IC50)|PKA|0.3 nM (IC50)|P70S6K|8.9 (IC50) [1]. Dong X, et al. Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design. J Med Chem. 2019 Aug 8;62(15):7264-7288. |